50P - Enumeration and molecular characterization of circulating tumor cells in lung cancer patients using the GILUPI CellCollector, an effective in vivo d...

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Lung and other Thoracic Tumours
Translational Research
Presenter Nicole Scheumann
Citation Annals of Oncology (2015) 26 (suppl_1): 10-14. 10.1093/annonc/mdv045
Authors N. Scheumann1, T. Gorges2, N. Penkalla3, B. Nowack4, T. Schalk3, S. Riethdorf2, K. Lücke5, K. Pantel2, T. Krahn6, C. Schumann7
  • 1Clinical Research, GILUPI GmbH, 14476 - Potsdam/DE
  • 2Tumour Biology, University Medical Center Hamburg-Eppendorf, Hamburg/DE
  • 3Pneumology, Ulm Medical University, Ulm/DE
  • 4Research And Development, GILUPI GmbH, Potsdam/DE
  • 5Ceo, GILUPI GmbH, Potsdam/DE
  • 6Global Biomarker Research, Bayer Pharma AG, Berlin/DE
  • 7Clinic For Pneumology, Thoracic Oncology, Sleep- And Respiratory Critical Care, Klinikum Kempten-Oberallgaeu gGmbH, Kempten/DE



Liquid biopsy - isolating and analysing circulating tumour cells (CTCs) from the blood of lung cancer patients - can provide additional information on prognosis, treatment efficacy and molecular tumour evolution. Currently, CTCs are isolated in vitro from limited volumes of patient blood samples. To overcome this limitation, an innovative device, the GILUPI CellCollectorTM, was used to isolate CTCs in vivo. Here, we conducted a comprehensive study deploying this effective device, to monitor CTC counts before initiation of chemotherapy and 12 weeks after in 50 lung patients. Further, we investigated the reproducibility of results, the correlation of the clinical response to CTC number changes, and mutations in CTCs of patients with known mutations in the primary tumour.


50 lung cancer patients (48 NSCLC and two SCLC) were screened for CTCs by two subsequent device applications before therapy initiation and 12 weeks after (n = 185 applications in total). Additionally, blood samples were analysed with the CellSearch® system. The CTC count change before and after therapy was correlated with clinical response. To analyse cancer specific mutations in CTCs captured with the GILUPI CellCollectorTM, digital PCR (dPCR) was performed.


Applying the GILUPI CellCollectorTM, CTCs were isolated from 78% of the patients during the pre-therapy visit. Overall, successful isolation of CTCs was significantly more frequent with the GILUPI CellCollectorTM (58%) compared to CellSearch® (28%). Furthermore, by using the GILUPI CellCollectorTM for CTC quantification before and after therapy initiation, an indication for responsive and non-responsive treatment outcomes was seen. Further, we were able to detect KRAS and EGFR mutations in CTCs known to be present in the primary tumour biopsy material.


The GILUPI CellCollectorTM overcomes blood volume limitations of other diagnostic approaches and thereby increases the diagnostic sensitivity of CTC isolation. It allows enumeration and molecular analysis of CTCs which might help to monitor therapy efficacy and improve treatment strategies.


K. Lücke: Is founder, shareholder and CEO of GILUPI GmbH and also patentee of the GILUPI CellCollectorTM. All other authors have declared no conflicts of interest.